BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, strengthens its Board of Directors with the appointment of Dr. Gary Gordon, an industry executive and a member of Israel Biotech Fund Venture Advisory Team.
Gamida Cell (NASDAQ: GMDA), announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant.
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share.
BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today the raising of a $19M Series C financing. The investment was led by Israel Biotech Fund, joined by SBI JI Innovation Fund, Arkin Bio Ventures and additional new and existing investors.
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced today the appointment of David S. Tierney M.D. as Chief Executive Officer, effective immediately as well as the establishment of a fully owned U.S. subsidiary to serve as the marketing base of the Company’s activities.
Ayala Pharmaceuticals announced preliminary results from its ongoing Phase 2 ACCURACY study of lead investigational new drug candidate, AL101, in patients with recurrent/metastatic adenoid cystic carcinoma (ACC) with progressing disease and Notch activating mutations.
On the back of the positive preclinical results and the recent $30 million financing round, Ayala is ready to start a phase 2 study of AL101 in TNBC. Separately, the drug is in a phase 2 trial in adenoid cystic carcinoma, with an FDA orphan drug designation.
Novartis has powered Ayala Pharmaceuticals to a $30 million series B round. Ayala will use the cash to fund mid-phase development of pan-Notch inhibitor AL101 in adenoid cystic carcinoma (ACC).
Ayala is looking to lead the way for the country’s burgeoning biotech sector and take its gamma secretase inhibitors all the way through to Phase III.
Ayala entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma.